030107_ColinGoddardtrue1334586686108acckfpUniversity Relations/Press releasepress releases, university relations, Colin, Goddard, lecture, distinguished, speakerColin Goddard, Ph.D., chief executive officer of OSI Pharmaceuticals, Inc. of Melville, will be the keynote speaker at the next Distinguished Lecture Series at Hofstra on Thursday, March 1, 2007 from 8-9:30 a.m. in the Rochelle and Irwin A. Lowenfeld Conference and Exhibition Hall, located on the 10th floor of the Joan & Donald E. Axinn Library, south campus (new location)./Hofstra_Main_Site/Home/News/PressReleases/Archive/030107_ColinGoddardprpsdv1175200680305sdwork11207940126961Press Release Sub TitleTopic will be “Are we winning the war on cancer?”Press Release TitleDR. COLIN GODDARD, CEO OF OSI PHARMACEUTICALS, TO GIVE DISTINGUISHED SPEAKER LECTUREPress Release Date2007/03/01Stu VincentUniversity RelationsHofstra Hall516-463-6493516-463-5146stuart.vincent@hofstra.edu//
Hofstra University, Hempstead, NY - Colin Goddard, Ph.D., chief executive officer of OSI Pharmaceuticals, Inc. of Melville, will be the keynote speaker at the next Distinguished Lecture Series at Hofstra on Thursday, March 1, 2007 from 8-9:30 a.m. in the Rochelle and Irwin A. Lowenfeld Conference and Exhibition Hall, located on the 10th floor of the Joan & Donald E. Axinn Library, south campus (new location).

The lecture, "Are we winning the war on cancer?" is presented by the  at Hofstra. Irwin Kellner, Ph.D., the Augustus B Weller Distinguished Chair of Economics at Hofstra, will be master of ceremonies.

Dr. Goddard has led OSI through a transition from a technology platform services company to an organization built around three units focused on oncology, diabetes and eye diseases. Under Dr. Goddard's leadership, OSI's flagship product, the cancer medication Tarceva®, was discovered and developed and obtained FDA approval for non-small cell lung cancer and pancreatic cancer.

Dr. Goddard has served OSI as director of drug discovery and pharmaceutical operations, vice president of research operations, executive vice president and chief operating officer, and president. He was also OSI's board chairman from 2000 to 2002. In March 2005, Dr. Goddard was named the first recipient of the New York Biotechnology Leadership Award by the New York Biotechnology Association. He delivered the commencement address and received an honorary degree at Hofstra's 2005 mid-year commencement. Before joining OSI, Dr. Goddard spent four years at the National Cancer Institute in Bethesda, Maryland. He trained as a cancer pharmacologist in Birmingham, England, and earned his Ph.D. from the University of Aston, also in Birmingham, in September 1985.

Dr. Goddard serves as a board member of the New York Biotechnology Association, Cancer Care of Long Island, the Long Island Association and The Winston Churchill Foundation of the United States. He is also a member of the American Association for Cancer Research.

Hofstra University is a dynamic private institution where students find their edge to succeed in more than 140 undergraduate and 155 graduate programs in liberal arts and sciences, business, communication, education and allied human services, and honors studies, and a School of Law.

###